ReviewInflammopharmacology2020
A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality.
Review in Inflammopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.Biomarker research · 2024Review
- Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Article
- Role of Inflammation in the Development of COVID-19 to Parkinson's Disease.Journal of inflammation research · 2024Article
- Ibuprofen, other NSAIDs and COVID-19: a narrative review.Inflammopharmacology · 2023Review
- Trends in Prescription Chronic Pain Medication Use before and during the First Wave of the COVID-19 Pandemic in Québec, Canada: An Interrupted Time Series Analysis.International journal of environmental research and public health · 2023Article
- Analgesics Induce Alterations in the Expression of SARS-CoV-2 Entry and Arachidonic-Acid-Metabolizing Genes in the Mouse Lungs.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Potential reversal of pulmonary vasoplegia by inhaled ibuprofenate in COVID-19 pneumonia.Clinical and translational discovery · 2022Article
- Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment.Biomedicines · 2022Review
- NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown?Inflammopharmacology · 2022Article
- Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.International journal of molecular sciences · 2022Article
- Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.PLoS pathogens · 2022Article
- Therapeutic Approaches in COVID-19 Patients: The Role of the Renin-Angiotensin System.Canadian respiratory journal · 2022Review
- Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave.Pharmacoepidemiology and drug safety · 2021Article
- Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.Immunity, inflammation and disease · 2021Review
- Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies.Viruses · 2021Review
- COVID-19: breaking down a global health crisis.Annals of clinical microbiology and antimicrobials · 2021Review
- Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.Nutrients · 2021Review
- Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 19 (COVID-19) pandemic is currently the most acute healthcare challenge in the world. Despite growing knowledge of the nature of Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2), treatment options are still poorly defined. The safety of non-steroidal anti-inflammatory drugs (NSAIDs), specifically ibuprofen, has been openly questioned without any supporting evidence or clarity over dose, duration, or temporality of administration. This has been further conflicted by the initiation of studies to assess the efficacy of ibuprofen in improving outcomes in severe COVID-19 patients. To clarify the scientific reality, a literature search was conducted alongside considerations of the pharmacological properties of ibuprofen in order to construct this narrative review. The literature suggests that double-blind, placebo-controlled study results must be reported and carefully analysed for safety and efficacy in patients with COVID-19 before any recommendations can be made regarding the use of ibuprofen in such patients. Limited studies have suggested: (i) no direct interactions between ibuprofen and SARS-CoV-2 and (ii) there is no evidence to suggest ibuprofen affects the regulation of angiotensin-converting-enzyme 2 (ACE2), the receptor for COVID-19, in human studies. Furthermore, in vitro studies suggest ibuprofen may facilitate cleavage of ACE2 from the membrane, preventing membrane-dependent viral entry into the cell, the clinical significance of which is uncertain. Additionally, in vitro evidence suggests that inhibition of the transcription factor nuclear factor-κB (NF-kB) by ibuprofen may have a role in reducing excess inflammation or cytokine release in COVID-19 patients. Finally, there is no evidence that ibuprofen will aggravate or increase the chance of infection of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.